In this work, we showed that treated tumors present a negative correlation in the spatial distribution of CD73 and Granzyme B + cells, suggesting therapies targeting CD73 may increase anti-tumor immunity throughout the tumor when impairing ADO pathway activation. This evidence concerns the gene NT5E and neoplasm.